Myelodysplastic Syndromes - Medicare Access (Medicare patients only)



Fund Type


Maximum Award Level


Pharmacy Card Fund


Household Income Limit

500% of the Federal Poverty Level
(adjusted for household size and high
cost of living areas)

Fund Alerts

Sign up for email or text/call alerts to receive instant notifications.

Treatments Covered

  • Aranesp
  • Atgam
  • Azacitidine Novaplus
  • Dacogen
  • Decitabine Novaplus
  • Epogen
  • Ethyol
  • Gleevec
  • Granix
  • Hycamptin
  • Inqovi
  • Jakafi
  • Leukine
  • Neoral (oral Only)
  • Neupogen
  • Nivestym
  • Nplate
  • Onureg
  • Premierpro Rx Azacitadine
  • Premierpro Rx Decitabine
  • Procrit
  • Promacta
  • Reblozyl
  • Retacrit
  • Revlimid
  • Sandimmune
  • Thalomid
  • Thymoglobulin
  • Tibsovo
  • Toposar
  • Topotecan Hcl
  • Tretinoin (oral Only)
  • Trisenox
  • Venclexta
  • Vidaza
  • Zarxio

Fund Definition

Assistance with the prescription drugs and biologics used in the treatment and management of Myelodysplastic Syndromes.

Grant Utilization

HealthWell estimates that patients use an average of $5,140 during their 12-month grant period for this disease area.

Consider Premium Assistance

Under this fund, HealthWell can assist with premium costs. Medicare supplemental policies can help with cost shares related to many aspects of your health care. Using a HealthWell grant to cover premiums may be a better option than treatment-specific cost shares.

Do I Qualify?

HealthWell bases eligibility on an individual’s medical, financial and insurance situation. To qualify for HealthWell’s assistance, applicants must meet the following eligibility requirements:

  • Please make sure that HealthWell currently has a fund for your diagnosis/indication and that your medication is covered under that fund by visiting our Disease Funds listing. If we do not have a fund that currently covers your diagnosis, please check back as we frequently open and reopen programs as funding becomes available. The Foundation is able to help patients receiving treatment for indications for which we currently have an open fund. We can only assist with medications that have been prescribed to treat the disease/covered diagnosis. You will be asked to provide the Foundation with the patient’s diagnosis, which must be verified by a physician, nurse practitioner, or physician assistant’s signature. The patient must receive treatment in the United States.

  • To qualify for assistance from HealthWell, you must have some form of health insurance (private insurance, Medicare, Medicaid, TriCare, etc.) that covers part of the cost of your treatment. The Foundation will refer patients without prescription insurance to other programs, such as manufacturer patient assistance programs.

  • HealthWell assists individuals with incomes up to 300-500% of the Federal Poverty Level. The Foundation also considers the number in a household and cost of living in a particular city or state. If you believe you qualify for assistance, you may begin the application process here.
  • If you are receiving treatment in the U.S. and have met the eligibility criteria as listed, you are ready to apply! Please note that you will be asked to provide a Social Security Number in order to create a grant. This information is gathered to eliminate duplicate applications and is kept secure and confidential.


About Myelodysplastic Syndromes

According to the National Cancer Institute, myelodysplastic syndromes are a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy red blood cells, white blood cells, or platelets. These immature blood cells, called blasts, do not work the way they should and either die in the bone marrow or soon after they go into the blood. Source: National Cancer Institute

Additional Resources

You may also visit our Resource List to view other copayment organizations that may provide assistance.

Close menu